Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)
Others
Ratios

Benitec Biopharma (BNTC) Income from Continuing Operations (2019 - 2025)

Benitec Biopharma's Income from Continuing Operations history spans 7 years, with the latest figure at 9365000.0 for Q1 2025.

  • For Q1 2025, Income from Continuing Operations fell 125.93% year-over-year to 9365000.0; the TTM value through Mar 2025 reached 29162000.0, down 35.54%, while the annual FY2024 figure was 21586000.0, 12.93% down from the prior year.
  • Income from Continuing Operations for Q1 2025 was 9365000.0 at Benitec Biopharma, up from 9982000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 3469000.0 in Q1 2022 and bottomed at 9982000.0 in Q4 2024.
  • The 5-year median for Income from Continuing Operations is 4748000.0 (2022), against an average of 5339470.59.
  • The largest annual shift saw Income from Continuing Operations grew 11.79% in 2024 before it plummeted 125.93% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 4846000.0 in 2021, then fell by 15.95% to 5619000.0 in 2022, then fell by 23.38% to 6933000.0 in 2023, then tumbled by 43.98% to 9982000.0 in 2024, then increased by 6.18% to 9365000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Income from Continuing Operations are 9365000.0 (Q1 2025), 9982000.0 (Q4 2024), and 5187000.0 (Q3 2024).